trial
as of 2026-07-01Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
NCTId NCT06494397
at a glance
Phase 1 · Completed
Enrollment 26 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2024-10-24
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
26 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2024-07-11
Primary completion
2024-10-24
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
3 total
Los Alamitos, United StatesGaithersburg, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
26
Phase
PHASE1
Primary Completion Date
2024-10-24
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication